HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

acivicin (AT 125)

RN given refers to cpd without isomeric desgination

Also Known As:

AT 125; AT-125; L-(alphaS,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid; NSC 163501; U 42,126; U-42,126; alpha-S,5S-alpha-amino-3-chloro-2-isoxazoline-5-acetic acid; alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid

Networked: 300 relevant articles (19 outcomes, 51 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 60
- 1-Ring Heterocyclic Compounds
  - Azoles: 413
    - Isoxazoles: 13
      - acivicin: 300

Experts

1.	Ingemansson, Richard: 3 articles (02/2011 - 09/2006)
2.	Malmsjö, Malin: 3 articles (02/2011 - 09/2006)
3.	Roy, Subhadra: 3 articles (01/2008 - 05/2005)
4.	Maity, Putul: 3 articles (01/2008 - 05/2005)
5.	Jobe, Alan H: 3 articles (01/2003 - 08/2002)
6.	Satoh, Shoji: 2 articles (02/2013 - 05/2011)
7.	Shiozaki, Arihiro: 2 articles (02/2013 - 05/2011)
8.	Matsuda, Yoshio: 2 articles (02/2013 - 05/2011)
9.	Saito, Shigeru: 2 articles (02/2013 - 05/2011)
10.	Kwiecień, Inga: 2 articles (01/2012 - 02/2007)

Related Diseases

1.	Neoplasms (Cancer) 03/30/1995 - "The cytotoxic agent acivicin has been shown to be effective against several types of tumors. " 04/17/2006 - "In at least one other study renal cell tumors were produced in male rats at 125 mg/L. " 01/01/1995 - "A phase I study of acivicin in refractory pediatric solid tumors. " 07/01/1983 - "Phase I study of acivicin in patients with advanced cancer." 11/01/2001 - "A new acivicin prodrug designed for tumor-targeted delivery."
2.	Weight Gain 06/14/2012 - "Mice were subjected for eight weeks to a standard diet (CHOW), a high fat diet (HFD; DIO group), or HFD to which Populus balsamifera was incorporated at 125 and 250 mg/kg. The results showed that Populus balsamifera decreased in a dose-dependent manner the weight gain of whole body, retroperitoneal fat pad and liver as compared to DIO controls and reduced the severity of hepatic macrovesicular steatosis and triglyceride accumulation. " 12/01/1996 - "In contrast, maternal corrected gestational weight gain increased at >/=125 mg/kg/day. " 09/01/1991 - "At Day 28, the three treatments containing NaNi and the treatment containing narasin at 60 ppm significantly improved weight gain and feed efficiencies over the two treatments containing nicarbazin at 125 ppm and the unmedicated controls. "
3.	Breast Neoplasms (Breast Cancer) 10/01/1986 - "Phase II clinical trial of acivicin in advanced breast cancer: an Eastern Cooperative Oncology Group Study." 09/01/1983 - "Phase II trial of acivicin in advanced metastatic breast cancer." 01/01/1993 - "More recently, a 6 month Phase I trial was completed in which patients with resected colon polyps, or females with first degree relatives with breast cancer, were given oral daily doses of oltipraz at 125 mg or 250 mg. The maximum tolerated dose of oltipraz was < or = 125 mg daily. " 08/01/2014 - "The trypsin inhibitor only slightly inhibited the viability of breast cancer MCF7 and hepatoma HepG2 cells at 125 μM." 09/01/1990 - "Concomitant Aminosyn treatment did not alter the efficacy of acivicin in mice bearing L1210 leukemia or MX-1 human mammary carcinoma. "
4.	Colorectal Neoplasms (Colorectal Cancer) 12/01/1987 - "We did not find acivicin given as described to be effective in colorectal carcinoma." 12/01/1987 - "The National Cancer Institute of Canada (NCIC) Clinical Trials Group has carried out a phase II study of acivicin given as a 72-hour continuous infusion in previously untreated patients with measurable metastatic colorectal carcinoma. " 12/01/1987 - "Phase II study of acivicin as a 72-hr continuous infusion in patients with untreated colorectal cancer. " 06/01/1986 - "Phase II trial of acivicin in patients with advanced colorectal carcinoma." 09/01/1984 - "Phase II study of acivicin in colorectal carcinoma: a National Cancer Institute of Canada study."
5.	Hepatocellular Carcinoma (Hepatoma) 12/01/1990 - "A randomized phase II study of acivicin and 4'deoxydoxorubicin in patients with hepatocellular carcinoma in an Eastern Cooperative Oncology Group study." 11/01/1982 - "The hydroxy analog of acivicin was also a competitive inhibitor, but it was less effective than acivicin, with a Ki value of 1.8 mM for the hepatoma enzyme. " 11/01/1982 - "The antiglutamine agent acivicin, L-(alpha S,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid, inhibited the growth of hepatoma 3924A cells in culture. " 11/01/1982 - "Biochemical pharmacology of acivicin in rat hepatoma cells." 01/15/1985 - "At acivicin doses of 1.0 and 5.0 mg/kg body weight, enzyme activity in the hepatoma decreased to 26 and 5%, respectively, after 2 hr. The activity of the in vivo inactivated hepatoma 3924A enzyme could not be restored by gel filtration or 40 hr of dialysis. "

Related Drugs and Biologics

1.	Glutamine (L-Glutamine)
2.	Aspartic Acid (Aspartate)
3.	amino-acid, glucose, and electrolyte solution (Novamine)
4.	gamma-Glutamyltransferase (gamma-Glutamyl Transpeptidase)
5.	Glutathione (Reduced Glutathione)
6.	tiazofurin
7.	NSC 224131 (PALA)
8.	K 76 carboxylic acid
9.	Nicarbazin
10.	Melphalan (Alkeran)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Aftercare (After-Treatment)
3.	Combination Drug Therapy (Combination Chemotherapy)
4.	Transplants (Transplant)
5.	Transplantation (Transplant Recipients)